Neisvac-C (Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated))

The vaccine contains tetanus toxoid, an adjuvant (algeldrate), and a de‑O‑acetylated polysaccharide from Neisseria meningitidis group C. After intramuscular injection, the antigens are taken up by immune cells, which present them to T cells, prompting B cells to produce specific antibodies that neutralize tetanus toxin and target the meningococcal capsule.

The dosage and schedule for Neisvac‑C are determined by the prescribing healthcare professional based on age, immunization history, and local guidelines. The product is supplied as a single‑dose injectable solution that is given intramuscularly, and the exact volume administered is specified by the prescriber.

Safety data for Neisvac‑C in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding is not expected to be contraindicated, but clinicians should evaluate each case individually.

To order Neisvac‑C, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Neisvac‑C combines tetanus toxoid with a polysaccharide from meningococcal group C, whereas many alternative products use conjugated polysaccharides linked to carrier proteins for enhanced immunogenicity. Both approaches protect against the same pathogens, but conjugate vaccines may elicit stronger memory responses, especially in young children. Choice depends on regulatory approvals, schedule requirements and local epidemiology.

Neisvac‑C must be stored in a refrigerated environment between 2 °C and 8 °C. It should be kept in the original packaging to protect from light, must not be frozen, and should not be shaken vigorously. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Neisvac‑C is administered as a single intramuscular injection, typically into the deltoid muscle of adults or the anterolateral thigh in infants and young children. The injection is performed by a qualified healthcare professional using aseptic technique, and the site should be observed for any immediate local reactions.

The most serious adverse events reported with Neisvac‑C include severe allergic reactions such as anaphylaxis, rare neurologic complications like Guillain‑Barré syndrome, and occasional febrile seizures in susceptible individuals. Prompt medical evaluation is required if symptoms such as difficulty breathing, swelling of the face or throat, or neurological changes occur after vaccination.

Neisvac‑C should not be given to persons with a documented severe allergy to any component of the vaccine, including tetanus toxoid, algeldrate or the meningococcal polysaccharide. Individuals who have experienced anaphylaxis after a previous dose of a similar vaccine should also avoid further administration. Contraindications are determined by the treating clinician.